NCT05178043 2024-02-22
GT90001 Plus Nivolumab in Patients With Advanced Hepatocellular Carcinoma
Suzhou Kintor Pharmaceutical Inc,
Phase 2 Unknown
Clinical Trials
7 trialsNCT01486368 2023-08-04
A Phase II Study of PF-03446962 in Patients With Advanced Malignant Pleural Mesothelioma
Canadian Cancer Trials Group
Phase 2 Completed
NCT01620970 2021-05-14
PF-03446962 in Relapsed or Refractory Urothelial Cancer
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Phase 2 Completed
NCT02116894 2019-03-14
REGAL-1
Duke University
Phase 1 Completed
NCT01337050 2015-10-28
Asian Phase I Study Of PF-03446962
Pfizer
Phase 1 Completed
NCT01911273 2015-10-28
A Study To Evaluate The Efficacy And Safety of The Investigational Drug PF-03446962 (A Monoclonal Antibody With Antiangiogenic Features) In Combination With Best Supportive Care Versus Placebo Plus Best Supportive Care In Patients Affected By Recurrent Liver Cancer
Pfizer
Phase 2 Terminated
NCT00557856 2015-10-19
A First In Patient, Study Of Investigational Drug PF-03446962 In Patients With Advanced Solid Tumors
Pfizer
Phase 1 Completed